Trial · NCT01632241
Adverse events480
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 480
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Placebo (DB Phase) | 14 | 165 | 20 |
| other | Upper respiratory tract infection | Infections and infestations | Belimumab 10 mg/kg (DB Phase) | 48 | 331 | 58 |
| other | Upper respiratory tract infection | Infections and infestations | Placebo to Belimumab 10 mg/kg (OL Phase) | 4 | 117 | 6 |
| other | Upper respiratory tract infection | Infections and infestations | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 20 | 242 | 21 |
| other | Urinary tract infection | Infections and infestations | Placebo (DB Phase) | 19 | 165 | 24 |
| other | Urinary tract infection | Infections and infestations | Belimumab 10 mg/kg (DB Phase) | 43 | 331 | 57 |
| other | Urinary tract infection | Infections and infestations | Placebo to Belimumab 10 mg/kg (OL Phase) | 7 | 117 | 7 |
| other | Urinary tract infection | Infections and infestations | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 13 | 242 | 15 |
| other | Headache | Nervous system disorders | Placebo (DB Phase) | 18 | 165 | 25 |
| other | Headache | Nervous system disorders | Belimumab 10 mg/kg (DB Phase) | 39 | 331 | 47 |
| other | Headache | Nervous system disorders | Placebo to Belimumab 10 mg/kg (OL Phase) | 0 | 117 | 0 |
| other | Headache | Nervous system disorders | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 0 | 242 | 0 |
| other | Influenza | Infections and infestations | Placebo (DB Phase) | 17 | 165 | 23 |
| other | Influenza | Infections and infestations | Belimumab 10 mg/kg (DB Phase) | 28 | 331 | 35 |
| other | Influenza | Infections and infestations | Placebo to Belimumab 10 mg/kg (OL Phase) | 7 | 117 | 8 |
| other | Influenza | Infections and infestations | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 16 | 242 | 18 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo (DB Phase) | 9 | 165 | 12 |
| other | Diarrhoea | Gastrointestinal disorders | Belimumab 10 mg/kg (DB Phase) | 31 | 331 | 34 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo to Belimumab 10 mg/kg (OL Phase) | 0 | 117 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase) | 0 | 242 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01632241/events